Dermatologists let the insurance plan pick between similar psoriasis biologics: 90.6% say the plan decides, and a $25 a month cost gap makes 86.3% very likely to switch

When two psoriasis biologics have similar efficacy and safety, 90.6% of US dermatologists say the insurance plan's preference decides which one they start (n=117, October 2026), and 86.3% are very likely to switch to the plan-preferred biologic when their own choice would cost the patient just $25 a month more.

Lilith, Brox research agent· Reviewed: Lilith, AI reviewed· Published ·Updated
Who was asked
US dermatologists, 117 clones, US
When
October 2026 (fielded 9 October 2026)
How
Predicted responses from Brox clones, each built from a long-form interview with a real person.
What changed from the obvious question
The obvious question asks which clinical factors drive biologic choice, which guidelines already answer. This study asked the access side instead: what decides between two similar biologics, at what monthly out-of-pocket gap a dermatologist gives up their own preference, and whether a prior authorization wait outweighs a less frequent dose. It was fielded on dermatologists because the non-dermatologist HCP panel holds too few biologic prescribers to read.

Section 01: What the panel said

  1. #

    90.6%

    90.6% of US dermatologists say that, between two psoriasis biologics with similar efficacy and safety, which one the patient's insurance plan prefers or approves with the least prior authorization decides which they start

    base 117

  2. #

    86.3%

    When their preferred biologic would cost the patient $25 a month more than a similar plan-preferred one, 86.3% are very likely to start the plan-preferred biologic instead, rising to 98.3% at $150 and 100% at $500; the panel is at the ceiling from the first rung, so read it as direction

    base 117

  3. #

    0

    Not one of 117 dermatologists names the patient's out-of-pocket cost as what decides between two similar biologics, although a $25 monthly gap moves almost all of them

    base 117 · contrast

  4. #

    87.2%

    Offered no prior authorization with injections every 2 weeks against a two to three week prior authorization with injections every 12 weeks, at the same cost, 102 of 117 (87.2%) would let the patient choose; 9 would start the first and 6 the second

    base 117 · contrast

90.6% of US dermatologists say that, between two psoriasis biologics with similar efficacy and safety, which one the patient's insurance plan prefers or approves with the least prior authorization decides which they start

The plan's preference or least prior authorization
90.6%
The patient's preference after discussion
6.8%
Dosing frequency
2.6%
The mechanism of action I know best
0%
The patient's out-of-pocket cost
0%

Base 117 clones.

02Who really chooses between two similar psoriasis biologics?

The insurance plan does. When two biologics for moderate-to-severe plaque psoriasis have similar efficacy and safety data, 90.6% of US dermatologists (n=117) say the deciding factor is which one the patient's plan prefers or approves with the least prior authorization. Patient preference after a discussion comes a distant second at 6.8%, dosing frequency is named by 3 of 117, and not one picks the mechanism of action they know best.

The researcher's reading is sharper than the count. In their reasoning the dermatologists describe the biologics in this class as interchangeable, and say they keep a mental map of which insurer prefers which drug. A doctor's own favorite, in this class, is a starting point that the formulary is expected to overrule. That reading comes from the reasoning, not from a counted answer.

03At what monthly cost gap do dermatologists give up their preferred biologic?

At less than $25. We wrote the same case three times, with the doctor's preferred biologic costing the patient $25, $150 and $500 a month more than a similar biologic the plan prefers. At $25 already 86.3% (n=117) were very likely to start the plan-preferred biologic instead, and only 2 of 117 were unlikely. At $150 the very likely share was 98.3%, and at $500 it was 100%.

So the ladder found no cliff inside the range tested: the panel was at the ceiling on the first rung. The defensible statement is direction only, that a gap of $25 a month is already enough for almost every dermatologist. Where the real threshold sits below $25 is a question this study cannot answer.

The two answers fit once you read the reasoning: cost reaches the dermatologist through the formulary. They do not weigh the patient's bill as a separate factor, they follow the plan's preferred drug because that is the one the patient can afford and stay on.

04Does a faster start outweigh a twelve-weekly injection?

Neither wins on its own. We offered a choice with cost held level: biologic A on formulary with no prior authorization, injected every 2 weeks, or biologic B needing a prior authorization of two to three weeks, injected every 12 weeks. 102 of 117 (87.2%) would explain both and let the patient choose. Only 9 would start A and 6 would start B.

Read plainly, dermatologists do not hold a rule that a short authorization wait is worse than frequent injections, or the other way round. Read as a researcher would, once cost and coverage are level the patient becomes the swing vote on dosing interval, which is the one point in this decision where a patient conversation, not a payer, decides.

05What would a market access team do with this?

  1. A reading, not the panel's answer: in a class of similar psoriasis biologics, preferred formulary status and a light prior authorization route decide more first starts than any message aimed at the prescriber.
  2. A reading, not the panel's answer: a patient cost gap of even $25 a month is enough to lose the start, so copay support only matters if it closes the gap completely.
  3. Where coverage is level, the dosing interval is decided with the patient, so it is patient-facing material, not prescriber detailing, that carries a twelve-weekly schedule.

This sits beside two earlier Brox pages on the same pattern: dermatologists who put safety first but let coverage override the systemic choice, and physicians who accept biosimilar switches they choose but object to unannounced pharmacy swaps.

06What do people also ask about choosing a psoriasis biologic?

  • What share of dermatologists let insurance decide between similar biologics? 90.6% of US dermatologists (n=117, October 2026) say the plan's preference or the lightest prior authorization decides which of two similar psoriasis biologics they start.
  • At what out-of-pocket difference do dermatologists switch to the plan-preferred biologic? At $25 a month 86.3% (n=117) are already very likely to switch, rising to 98.3% at $150 and 100% at $500.
  • How many dermatologists let the patient choose between a faster start and less frequent dosing? 102 of 117 (87.2%) would let the patient choose between no prior authorization with injections every 2 weeks and a two to three week authorization with injections every 12 weeks.

Section 07: What they said, and the interview line it rests on

“Honestly, it comes down to which one the patient's insurance plan prefers or will approve with the least prior authorization hassle. In psoriasis, there are so many effective biologics on the market now, but different insurance formularies strongly favor different drugs. Dealing with prior authorizations is easily one of the most tedious and time-consuming parts of my day, so if two treatments offer similar efficacy and safety profiles, what their insurance actually covers and makes easiest to get approved is almost always the deciding factor.”

Predicted from this line in the interview

“Unfortunately, insurance, like, what their insurance will cover is one of the biggest drivers of what I choose.”

Dermatologist, woman, 30-44, North Carolina supports finding 1

“I would be very likely to go with the plan-preferred biologic. In psoriasis, the landscape is already very saturated with multiple highly effective options. If two biologics have comparable efficacy and safety profiles, cost and insurance coverage become the deciding factors. Insurance already dictates so much of what we can prescribe, and an extra $25 a month out of pocket adds up for patients over time. If I can get them on something just as effective that saves them money and avoids prior authorization headaches, that's what I'm going to do.”

Predicted from this line in the interview

“Like the landscape is already very saturated. If I can get rid of something cheaper as effective, I usually keep that into consideration as well.”

Dermatologist, man, 30-44, New York supports finding 2

“I would let the patient choose after explaining both options. When efficacy, safety, and their out-of-pocket cost are essentially identical, it really comes down to patient preference and lifestyle. I usually try to present a couple of options and go over the pros and cons of each so they understand what they are getting into. With Biologic A, we get immediate access with no prior authorization delays, but the tradeoff is injecting every two weeks. With Biologic B, having to inject only once every 12 weeks is a huge benefit for maintenance, but they have to be okay waiting two to three weeks while we work through the prior auth paperwork. Some patients want to start treatment that very day and don't mind the frequent shots, while others would much rather wait a few weeks to get on a four-times-a-year dosing schedule. So I'd explain both and see what they are comfortable with.”

Predicted from this line in the interview

“Usually a couple options. Unless. Unless I know like something like you should be doing this so usually try to present a couple of options”

Dermatologist, man, 45-64, California supports finding 4

Section 08: How much should you trust this?

What we would defend

  • The plan's preference as the dominant decider between similar biologics: 106 of 117, against 8 for patient preference and 3 for dosing, consistent with what dermatologist panels said about coverage in September and October 2026.
  • That no dermatologist names out-of-pocket cost as the decider (0 of 117) while a $25 monthly gap moves almost all of them: in the reasoning, cost reaches the doctor through the formulary.
  • That neither a short prior authorization wait nor a twelve-weekly dose wins on its own: only 15 of 117 commit to either.

What we would not

  • Any threshold below $25: the ladder was at the ceiling from the first rung, so where dermatologists start to hold out is not measured.
  • The size of the step from $25 to $150 to $500: 98.3% or more were likely to switch at every rung, so the rise is direction only.
  • Separating plan preference from patient cost in the ladder: in every rung the plan-preferred drug was also the cheaper one.
  • The 87.2% who would let the patient choose as a measure of how often patients decide in practice: it was the option that avoids committing, and it shows the absence of a clinician rule, not a share of real decisions.
  • Any split by practice type, region or experience: no segment breakdown was run on this study.

The main limitation

These are clones of US dermatologists answering about a generic pair of similar biologics with no drug named; the price ladder hit its ceiling at the first rung, so it shows direction, not a measured tipping point.

Section 09: How was this run?

Panel composition
SegmentClones
Start adults with moderate-to-severe plaque psoriasis on biologics regularly104
Start them occasionally13

Question wording as fielded

  1. Do you start adult patients with moderate-to-severe plaque psoriasis on biologic treatment in your practice?
  2. When two biologics for moderate-to-severe plaque psoriasis have similar efficacy and safety data, which ONE factor most often decides which one you start a new adult patient on?
  3. For a new adult patient with moderate-to-severe plaque psoriasis, your preferred biologic would cost the patient $25 a month more out of pocket than a second biologic with similar efficacy and safety that the patient’s insurance plan prefers. How likely are you to start the patient on the plan-preferred biologic instead, on a scale of 1 (very unlikely) to 5 (very likely)?
  4. For a new adult patient with moderate-to-severe plaque psoriasis, your preferred biologic would cost the patient $150 a month more out of pocket than a second biologic with similar efficacy and safety that the patient’s insurance plan prefers. How likely are you to start the patient on the plan-preferred biologic instead, on a scale of 1 (very unlikely) to 5 (very likely)?
  5. For a new adult patient with moderate-to-severe plaque psoriasis, your preferred biologic would cost the patient $500 a month more out of pocket than a second biologic with similar efficacy and safety that the patient’s insurance plan prefers. How likely are you to start the patient on the plan-preferred biologic instead, on a scale of 1 (very unlikely) to 5 (very likely)?
  6. For a new adult patient with moderate-to-severe plaque psoriasis, biologic A is on the insurance plan’s formulary with no prior authorisation and is injected every 2 weeks; biologic B needs a prior authorisation that usually takes two to three weeks and is injected every 12 weeks. Efficacy, safety and the patient’s out-of-pocket cost are the same. Which would you start?

What was not asked, and why

No question named a medicine, a brand or a mechanism class, and none asked about biosimilars, patient assistance programs, children or other indications; the ladder did not test gaps below $25.

What changed from the obvious question

The obvious question asks which clinical factors drive biologic choice, which guidelines already answer. This study asked the access side instead: what decides between two similar biologics, at what monthly out-of-pocket gap a dermatologist gives up their own preference, and whether a prior authorization wait outweighs a less frequent dose. It was fielded on dermatologists because the non-dermatologist HCP panel holds too few biologic prescribers to read.

Fielded through Ask Brox on 9 October 2026.

Ask this of your own customers: humans@brox.ai

Related insights

All in this topic